Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Drug

CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume

Fineline Cube Nov 1, 2024

The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...

Company Drug

AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China

Fineline Cube Nov 1, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...

Company Drug

Eisai and Biogen Complete BLA Submission for Alzheimer’s Drug Leqembi to FDA

Fineline Cube Nov 1, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the completion...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study

Fineline Cube Nov 1, 2024

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company

Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance

Fineline Cube Nov 1, 2024

US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...

Company Drug

Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study

Fineline Cube Nov 1, 2024

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US...

Company Deals

HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales

Fineline Cube Nov 1, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...

Company Drug

Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial

Fineline Cube Nov 1, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New...

Company Drug

Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study

Fineline Cube Nov 1, 2024

China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...

Company Drug

Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY

Fineline Cube Nov 1, 2024

China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Wins UK Approval for NSCLC Treatment

Fineline Cube Oct 31, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has received marketing approval from the UK Medicines and Healthcare...

Company

Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales

Fineline Cube Oct 31, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third...

Company

Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase

Fineline Cube Oct 31, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter...

Company Deals

HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments

Fineline Cube Oct 31, 2024

Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced a strategic cooperation agreement with...

Company

Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY

Fineline Cube Oct 31, 2024

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024,...

Company

Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses

Fineline Cube Oct 31, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter...

Company Deals

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch

Fineline Cube Oct 31, 2024

China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical...

Company

Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound

Fineline Cube Oct 31, 2024

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for...

Company

AstraZeneca China President Leon Wang Involved in Chinese Investigation Amid Industry Probes

Fineline Cube Oct 31, 2024

Leon Wang, Executive Vice President International and AstraZeneca (AZ, NASDAQ: AZN) China President, is cooperating...

Company Drug

AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China

Fineline Cube Oct 31, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of...

Posts pagination

1 … 229 230 231 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.